Aclaris Therapeutics, Inc. - ACRS

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Aug 14, 2026 SCHEDULE 13G/A RA Capital Management, L.P. 9.1% 12,723,026 View
Aug 14, 2026 SCHEDULE 13G/A Peter Kolchinsky 9.1% 12,723,026 View
Aug 14, 2026 SCHEDULE 13G/A Rajeev Shah 9.1% 12,723,026 View
Aug 14, 2026 SCHEDULE 13G/A RA Capital Healthcare Fund, L.P. 9.1% 12,723,026 View
May 12, 2026 SCHEDULE 13G/A Vivo Opportunity Fund Holdings, L.P. 4.3% 5,966,370 View
May 12, 2026 SCHEDULE 13G/A Vivo Opportunity, LLC 4.3% 5,966,370 View
May 12, 2026 SCHEDULE 13G/A Vivo Opportunity Cayman Fund, L.P. 0.5% 700,296 View
May 12, 2026 SCHEDULE 13G/A Vivo Opportunity Cayman, LLC 0.5% 700,296 View
Apr 27, 2026 SCHEDULE 13G/A BML Investment Partners, L.P. 9.9% 13,950,000 View
Apr 07, 2026 SCHEDULE 13G RA Capital Management, L.P. 6.3% 7,626,705 View
Apr 07, 2026 SCHEDULE 13G Peter Kolchinsky 6.3% 7,626,705 View
Apr 07, 2026 SCHEDULE 13G Rajeev Shah 6.3% 7,626,705 View
Apr 07, 2026 SCHEDULE 13G RA Capital Healthcare Fund, L.P. 6.3% 7,626,705 View
Mar 26, 2026 SCHEDULE 13G/A The Vanguard Group 0.0% 0 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.